Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse.

[1]  Theresa A. Storm,et al.  Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. , 2003, Blood.

[2]  Yuqin Wang,et al.  Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. , 2003, The Journal of clinical investigation.

[3]  C. Peters,et al.  Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines , 2003, Bone Marrow Transplantation.

[4]  M. Haskins,et al.  Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  Theresa A. Storm,et al.  A Limited Number of Transducible Hepatocytes Restricts a Wide-Range Linear Vector Dose Response in Recombinant Adeno-Associated Virus-Mediated Liver Transduction , 2002, Journal of Virology.

[6]  R. Herzog,et al.  Improved Hepatic Gene Transfer by Using an Adeno-Associated Virus Serotype 5 Vector , 2002, Journal of Virology.

[7]  M. Hancock,et al.  I-type lectins. , 2002 .

[8]  C. Elliger,et al.  Enhanced secretion and uptake of beta-glucuronidase improves adeno-associated viral-mediated gene therapy of mucopolysaccharidosis type VII mice. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  E. Kakkis.  Enzyme replacement therapy for the mucopolysaccharide storage disorders , 2002, Expert opinion on investigational drugs.

[10]  R. Herzog,et al.  Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. , 2002, Blood.

[11]  Xiao‐Kang Li,et al.  Prolongation of transgene expression by coexpression of cytokine response modifier a in rodent liver after adenoviral gene transfer. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  M. Sands,et al.  Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer , 2001, Gene Therapy.

[13]  W. Sly,et al.  Murine Mucopolysaccharidosis VII: Impact of Therapies on the Phenotype, Clinical Course, and Pathology in a Model of a Lysosomal Storage Disease , 2001, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[14]  Haibin Xia,et al.  The HIV Tat protein transduction domain improves the biodistribution of β-glucuronidase expressed from recombinant viral vectors , 2001, Nature Biotechnology.

[15]  I. Martins,et al.  In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  C. Walsh,et al.  Induction of tolerance to human factor VIII in mice. , 2001, Blood.

[17]  A. Nienhuis,et al.  Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. , 2001, Blood.

[18]  W. Sly,et al.  Active site mutant transgene confers tolerance to human β-glucuronidase without affecting the phenotype of MPS VII mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Sands,et al.  Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells. , 2000, Human gene therapy.

[20]  M. Haskins,et al.  Delivery of a retroviral vector expressing human beta-glucuronidase to the liver and spleen decreases lysosomal storage in mucopolysaccharidosis VII mice. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  T. Daly,et al.  Abnormal Immune Function In Vivo in a Murine Model of Lysosomal Storage Disease , 2000, Pediatric Research.

[22]  H. Hamada,et al.  Adenovirus-mediated gene therapy for mucopolysaccharidosis VII: involvement of cross-correction in wide-spread distribution of the gene products and long-term effects of CTLA-4Ig coexpression. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  Theresa A. Storm,et al.  Nonrandom Transduction of Recombinant Adeno-Associated Virus Vectors in Mouse Hepatocytes In Vivo: Cell Cycling Does Not Influence Hepatocyte Transduction , 2000, Journal of Virology.

[24]  Philip R. Johnson,et al.  Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse. , 2000, Human gene therapy.

[25]  M. Kay,et al.  Isolation of Recombinant Adeno-Associated Virus Vector-Cellular DNA Junctions from Mouse Liver , 1999, Journal of Virology.

[26]  Philip R. Johnson,et al.  Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. , 1999, Human gene therapy.

[27]  B. Davidson,et al.  Systemic and Central Nervous System Correction of Lysosomal Storage in Mucopolysaccharidosis Type VII Mice , 1999, Journal of Virology.

[28]  T. Daly,et al.  Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  C. Elliger,et al.  Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus , 1998, Gene Therapy.

[30]  James M. Wilson,et al.  Adeno-Associated Virus as a Vector for Liver-Directed Gene Therapy , 1998, Journal of Virology.

[31]  A. Gown,et al.  Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors , 1997, Nature Genetics.

[32]  J. Wolfe,et al.  Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of β-glucuronidase , 1997, Nature Medicine.

[33]  P. Johnson,et al.  Gene transfer to the intestinal tract: a new approach using selective injection of the superior mesenteric artery. , 1997, Human gene therapy.

[34]  W. Sly,et al.  Adenovirus-mediated gene transfer and expression of human beta-glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  K. Clark,et al.  A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. , 1996, Gene therapy.

[36]  L. Wang,et al.  Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. , 1996, Gene therapy.

[37]  Philip R. Johnson,et al.  Cell lines for the production of recombinant adeno-associated virus. , 1995, Human gene therapy.

[38]  F. Ledley,et al.  Retroviral gene transfer into the intestinal epithelium. , 1995, Human gene therapy.

[39]  A. Hille-Rehfeld.  Mannose 6-phosphate receptors in sorting and transport of lysosomal enzymes. , 1995, Biochimica et biophysica acta.

[40]  A. Varki,et al.  I-type Lectins (*) , 1995, The Journal of Biological Chemistry.

[41]  M. Sands,et al.  A single-base-pair deletion in the beta-glucuronidase gene accounts for the phenotype of murine mucopolysaccharidosis type VII. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  W. Sly,et al.  Increased life span and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation. , 1991, Blood.

[43]  E. Rinchik,et al.  DNA determinants of structural and regulatory variation within the murine beta-glucuronidase gene complex , 1989, Molecular and cellular biology.

[44]  S. Nagata,et al.  Isolation and characterization of the human chromosomal gene for polypeptide chain elongation factor-1 alpha. , 1989, The Journal of biological chemistry.

[45]  M. Davisson,et al.  Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency. , 1989, The Journal of clinical investigation.

[46]  J. F. Catterall,et al.  Genomic organization and sequence of the Gus-s alpha allele of the murine beta-glucuronidase gene , 1988, Molecular and cellular biology.

[47]  W. Sly,et al.  Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. , 1973, The Journal of pediatrics.

[48]  J. Wilson,et al.  Selective repopulation of normal mouse liver by hepatocytes transduced in vivo with recombinant adeno-associated virus. , 2001, Human gene therapy.

[49]  T. Daly,et al.  Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice. , 1999, Human gene therapy.

[50]  J. W. Kyle.  14 – β-Glucuronidase (GUS) Assay in Animal Tissue , 1992 .

[51]  S. Kornfeld.  Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. , 1992, Annual review of biochemistry.

[52]  S. Gallagher.  GUS protocols: using the GUS gene as a reporter of gene expression. , 1992 .

[53]  W. Sly,et al.  A murine model of mucopolysaccharidosis VII. Gross and microscopic findings in beta-glucuronidase-deficient mice. , 1990, The American journal of pathology.